Preanalytical considerations in detection of colorectal cancer in blood serum using Raman molecular imaging (Conference Presentation)

Author(s):  
Patrick J. Treado ◽  
Shona D. Stewart ◽  
Aaron Smith ◽  
Heather Kirschner ◽  
Christopher Post ◽  
...  
2008 ◽  
Vol 14 (22) ◽  
pp. 7413-7422 ◽  
Author(s):  
H. Charles Manning ◽  
Nipun B. Merchant ◽  
A. Coe Foutch ◽  
John M. Virostko ◽  
Shelby K. Wyatt ◽  
...  

2008 ◽  
Vol 144 (2) ◽  
pp. 310
Author(s):  
H. Charles Manning ◽  
Nipun B. Merchant ◽  
Allan Coe Foutch ◽  
Jack Viostko ◽  
Shelby K. Wyatt ◽  
...  

2010 ◽  
Vol 299 (4) ◽  
pp. G807-G820 ◽  
Author(s):  
Rahul A. Sheth ◽  
Umar Mahmood

Colorectal cancer remains a major cause of morbidity and mortality in the United States. The advent of molecular therapies targeted against specific, stereotyped cellular mutations that occur in this disease has ushered in new hope for treatment options. However, key questions regarding optimal dosing schedules, dosing duration, and patient selection remain unanswered. In this review, we describe how recent advances in molecular imaging, specifically optical molecular imaging with fluorescent probes, offer potential solutions to these questions. We begin with an overview of optical molecular imaging, including discussions on the various methods of design for fluorescent probes and the clinically relevant imaging systems that have been built to image them. We then focus on the relevance of optical molecular imaging to colorectal cancer. We review the most recent data on how this imaging modality has been applied to the measurement of treatment efficacy for currently available as well as developmental molecularly targeted therapies. We then conclude with a discussion on how this imaging approach has already begun to be translated clinically for human use.


2008 ◽  
Vol 134 (4) ◽  
pp. A-48 ◽  
Author(s):  
Martin Goetz ◽  
Alex Ziebart ◽  
Michael Vieth ◽  
Peter M. Delaney ◽  
Peter R. Galle ◽  
...  

2012 ◽  
Vol 11 (5) ◽  
pp. 7290.2012.00003 ◽  
Author(s):  
Rahul A. Sheth ◽  
Alexandra Kunin ◽  
Lars Stangenberg ◽  
Mark Sinnamon ◽  
Kenneth E. Hung ◽  
...  

2019 ◽  
Vol 30 ◽  
pp. iv1
Author(s):  
M. Kruchinina ◽  
A. Gromov ◽  
I. Prudnikova ◽  
M. Shashkov ◽  
A. Sokolova ◽  
...  

2016 ◽  
Vol 7 (3) ◽  
pp. 285-309 ◽  
Author(s):  
Roberto García-Figueiras ◽  
Sandra Baleato-González ◽  
Anwar R. Padhani ◽  
Ana Marhuenda ◽  
Antonio Luna ◽  
...  

Author(s):  
Hao Jiang ◽  
Wei Guo ◽  
Kuan Huang ◽  
Huijie Jiang ◽  
Rongjun Zhang ◽  
...  

Abstract Background Metastasis-associated in colon cancer 1 (MACC1) and Spondin2 (SPON2) are newly discovered oncogenes, but little is known about their role in colorectal cancer(CRC) liver metastases. PET has become an important molecular imaging technology due to its high sensitivity and quantifiability. In particular, its targeted, specific molecular probes can detect biological behaviors. This study was designed to evaluate the different biological properties of 18F-FDG, 18F-FLT, and 18F-FMISO PET. The value of the CRC liver metastasis model explores the correlation and potential mechanisms of three tracers uptakes with tumor-related biological characteristics. Methods Human CRC cell lines(LoVo and HCT8), were cultured for in vitro radionuclide uptake experiments to compare the molecular imaging features of colorectal cancer cells with different metastatic potentials. Two kinds of cells were injected into the spleen of nude mice to establish a liver metastasis model. After the tumor formation, three kinds of tracer PET images were performed to evaluate the characteristics of live PET imaging of high and low liver metastasis colorectal cancer models. The expression levels of MACC1 and SPON2 in tissues were detected by immunohistochemistry and Western blot. Correlation between tracer uptake and expression of MACC1 and SPON2 in liver metastases was assessed by linear regression analysis. Results The uptake rate of in vitro three tracers uptake experiments was LoVo > HCT8. Micro-PET scan showed no significant difference between the 18F-FDG SUV values of the two cells (P > 0.05); there was significant difference between the 18F-FLT and 18F-FMISO SUV values (P < 0.05). All in vivo FLT and FMISO SUV values were significantly higher in LoVo tumors than in HCT8 tumors. The results of Western blot and immunohistochemistry showed that the expression levels of MACC1 and SPON2 in LoVo liver metastasis were higher than those in HCT8 (P < 0.05). The 18F-FLT SUVmax ratio was significantly correlated with the expression of MACC1 and SPON2 in hepatic metastases (r = 0.737, P = 0.0026; r = 0.842, P = 0.0002). The 18F-FMISO SUVmax ratio was only significantly correlated with the expression of MACC1 in hepatic metastasis (r = 0.770, P = 0.0013). Conclusions Early screening with 18F-FLT and 18F-FMISO tracers has important clinical value for the efficient diagnosis and treatment of colorectal cancer liver metastases.


Sign in / Sign up

Export Citation Format

Share Document